At Emerald Bioscience, we are focused on advancing the medical benefits of cannabinoid-based therapies through our novel, proprietary, multi-cannabinoid drug platform for the treatment of significant unmet medical needs. This bioengineered platform, pioneered by the University of Mississippi, is considered an early mover in cannabinoid drug development. Modifying the molecules of the cannabis plant and creating synthetic cannabinoid derivatives, results in an optimized cannabinoid technology that enhances bioavailability and delivers more predictable pharmacokinetics.
Meet Our Team
Glaucoma. MRSA. Dry Eye Syndrome.
See the world's future through the potential of our proprietary cannabinoid-based therapies.
Our proprietary therapies continue to advance through preclinical and clinical development for various global medical indications.
Our platform is designed to enhance bioavailability and deliver more predictable pharmacokinetics.
Emerald Bioscience continues to establish relationships with industry leaders to further advance our research.
What are Cannabinoids?
August 26, 2019 | Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
August 13, 2019 | Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study
June 4, 2019 | Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
May 29, 2019 | Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi
Sign up for our Newsletter
Receive breaking news first!